ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Monday, October 27, 2025

10:30AM-12:30PM: Abstract Number: 1627

A systematic literature review to inform the 2025 EULAR recommendations for management of Polymyalgia Rheumatica and Large Vessel Vasculitis: management of disease including relapse and complications

(1612–1632) Vasculitis – Non-ANCA-Associated & Related Disorders Poster II

10:30AM-12:30PM: Abstract Number: 1614

A Systematic Literature Review to Inform the EULAR Recommendations for the Management of Polymyalgia Rheumatica and Large Vessel Vasculitis: Focus on Referral and Diagnosis

(1612–1632) Vasculitis – Non-ANCA-Associated & Related Disorders Poster II

10:30AM-12:30PM: Abstract Number: 1170

A20 Haploinsufficiency (HA20): TNFAIP3 Mutation Prevalence In A Clinically Compatible Cohort

(1147–1190) Miscellaneous Rheumatic & Inflammatory Diseases Poster II

10:30AM-12:30PM: Abstract Number: 1124

ABCG2 Variants as Genetic Risk Factors for Hyperuricemia and Gout: Focus on Pediatric and Familial Manifestations

(1123–1146) Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I

10:30AM-12:30PM: Abstract Number: 1022

Abuse in Rheumatic Diseases: Associations with Depression, Disability, and Psychosocial Risk Factors

(1007–1037) Epidemiology & Public Health Poster II

10:30AM-12:30PM: Abstract Number: 1007

Accelerometry-Derived Activity and Sleep Patterns in the NIH All of Us Cohort: Insights and Predictive Potential for Inflammatory Arthritis

(1007–1037) Epidemiology & Public Health Poster II

10:30AM-12:30PM: Abstract Number: 1084

Access to rheumatology care in patients with new diagnosis of polymyalgia rheumatica: analysis from a national inception cohort

(1055–1087) Healthcare Disparities in Rheumatology Posters

10:30AM-12:30PM: Abstract Number: 1349

Achievement of Treatment Targets and Maintenance of Response with Upadacitinib in Patients with Moderate-To-Severe Rheumatoid Arthritis in a Real-World Setting: Final 2-year Outcomes from the UPHOLD Study

(1347–1375) Rheumatoid Arthritis – Treatment Poster II

10:30AM-12:30PM: Abstract Number: 1531

Achieving Remission and Low Disease Activity with Belimumab Versus Placebo in Patients with SLE Excluding the Glucocorticoid Component from Target Definitions: A Post Hoc Analysis of Five Phase 3 Trials

(1517–1552) Systemic Lupus Erythematosus – Treatment Poster II

10:30AM-12:30PM: Abstract Number: 1497

Acute Care Utilization in Patients with Antiphospholipid Syndrome and/or Systemic Lupus Erythematosus

(1467–1516) Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes Poster II

10:30AM-12:30PM: Abstract Number: 1290

Adverse Childhood Experiences: Prevalence and Relationship to Disease and Mental Health Outcomes in Childhood-Onset Systemic Lupus Erythematosus (cSLE)

(1272–1305) Pediatric Rheumatology – Clinical Poster II

10:30AM-12:30PM: Abstract Number: 1065

Age of Disease Onset and Risk of Serious Infection with anti-TNF Use in Older Adults with Rheumatoid Arthritis

(1055–1087) Healthcare Disparities in Rheumatology Posters

10:30AM-12:30PM: Abstract Number: 1006

AI-Guided Generation and Preclinical Evaluation of an OX40L-IL31 Bispecific Antibody

(0978–1006) T Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster

10:30AM-12:30PM: Abstract Number: 1013

All roads lead to Rheum? Modeling scenarios of new patients-to-pediatric rheumatologist ratios in different US states

(1007–1037) Epidemiology & Public Health Poster II

10:30AM-12:30PM: Abstract Number: 0899

Altered B cell Subsets Shared in Immune Checkpoint Inhibitor Associated Sicca Syndrome and Sjogren’s Disease

(0897–0915) B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster II

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].